More on BEAM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $25.17 |
|
|||
| Open | $24.76 | ||||
| 52 Wk High | $83.60 | ||||
| 52 Wk Low | $82.96 | ||||
| Day High | $24.89 | ||||
| Day Low | $23.98 | ||||
| P/E | 10.88 | ||||
| EPS | $2.24 | ||||
| Volume | 1,964,906 | ||||
- Beam Therapeutics shares updated BEAM-302 trial data at ERS 2026
- Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
- Beam Therapeutics names Eric Foster as chief commercial officer
- Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
- Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
- H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
- Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: ARK Investment Management LLC
- Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
- H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
- Beam Therapeutics Inc (BEAM) PT Raised to $240 at JPMorgan
Entities mentioned with BEAM
- Earnings | View Related Stories »
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Show More...
